Moderna, Inc. Common Stock
MRNAModerna, Inc. (MRNA) is a biotechnology company specializing in messenger RNA (mRNA) technology to develop vaccines and therapeutics. Founded in 2010, it gained prominence with its COVID-19 vaccine, playing a key role in the global response to the pandemic. Moderna focuses on innovative mRNA solutions for infectious diseases, cancer, rare diseases, and other conditions.
Company News
Precious and industrial metals surged on December 26, 2025, with silver up 6% to $76/oz, platinum up 8%, and palladium up 11%, driven by supply crunches in Asian markets. Silver and platinum are on track for their best years since 1978 and on record, respectively. Gold rose 1.3% to $4,550/oz while copper climbed 4.6%. Among equities, copper produ...
The global nanobiotechnology market is projected to grow from USD 172.81 billion in 2024 to USD 420.2 billion by 2034, driven by healthcare demand, R&D funding, and technological innovations in drug delivery and medical applications.
Vertex Pharmaceuticals is expected to expand beyond its cystic fibrosis market dominance, with promising developments in pain medication, blood disorders, diabetes treatment, and kidney disease therapies. The company could potentially reach a market cap of $250 billion by 2030.
Pharmaceutical stocks rallied after Pfizer reached an agreement with the Trump administration to sell drugs at significant discounts, avoiding potential 100% tariffs. Multiple pharma companies saw substantial stock price increases.
Merck's stock has underperformed the industry, sector, and S&P 500 this year due to various challenges, including the upcoming patent expiration of its blockbuster drug Keytruda in 2028 and declining sales of its Gardasil vaccine in China. However, the company has a promising pipeline and new products that could drive long-term growth.
